Prolonged oral etoposide for refractory advanced uterine leiomyosarcoma.
The case of a patient with a uterine leiomyosarcoma (LMS) that rapidly recurred in the pelvis following primary surgery is reported. The tumor was refractory to conventional multiagent chemotherapy that included intravenously administered etoposide (VP-16). Etoposide was then administered orally in a prolonged schedule; this resulted in a sustained partial response with palliation of symptoms. Thus, prolonged oral administration of etoposide may have antitumor activity against LMS despite that tumor's resistance to short-term infusion schedules of etoposide.
Chantarawiroj
P
P
Rajvithi Hospital, Bangkok, Thailand.
Tresukosol
D
D
Kudelka
A P
AP
Edwards
C L
CL
Silva
E G
EG
Wharton
J T
JT
Kavanagh
J J
JJ
D000284:Administration, Oral; D000368:Aged; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007890:Leiomyosarcoma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D005047:Etoposide